Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Experimental Cancer Medicine Centres | OTHER |
| The Eve Appeal | UNKNOWN |
| Southampton Clinical Trials Unit | UNKNOWN |
| Daye BioTech |
Not provided
Not provided
Not provided
Not provided
This study will investigate vaginal secretions in those patients with cancer versus those who are cancer free and compare changes in specific markers that change when a cancer first develops.
Patients who are being investigated for any gynaecological cancer, undergoing surgery to reduce their risk of gynaecological cancer and those with confirmed gynaecological cancer undergoing anti-cancer treatment will be approached to take part in this study.
Participants will be asked to provide an extra blood test, urine sample and high vaginal swab in addition to surplus primary tissue and ascitic fluid that is left over from routine surgical procedures. Specific markers will be compared in patients who have evidence of gynaecological cancer versus those that do not. Changes in these markers during anti-cancer treatment will also be compared to see how these change over time. This could improve the detection and monitoring of gynaecological cancers in those people at highest risk of developing it by using non-invasive multi-cancer early detection tests developed at the University of Southampton.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Suspected for Gynaecological Cancers | Individuals undergoing investigations for suspected gynaecological cancer. Includes those undergoing surgery to reduce their risk of the development of gynaecological cancers in the future. | ||
| Confirmed Gynaecological Cancer | Individuals with a confirmed gynaecological cancer diagnosis undergoing anti-cancer treatment including surgical resection, chemotherapy or radiotherapy as part of their routine clinical care. | ||
| Confirmed Palliative Gynaecological Cancer | Individuals with a confirmed gynaecological cancer diagnosis undergoing palliative procedures including ascitic drainage as part of their routine clinical care. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Development of a non-invasive diagnostic and prognostic tool for the detection and monitoring of gynaecological cancers using biomarkers in vaginal fluid. | Sequential exploratory analysis of vaginal fluid will be undertaken, such as microbiome, genomic, epigenomic, metabolomic, transcriptomic and phenotypic analysis. This data will be compared with multiomics analysis of paired tissue plus plasma/blood/urine/ascitic fluid then correlated with clinical outcome. | From enrolment to 5 years post last participant enrolled |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Participants will be identified by clinically- and research-trained investigators from routine clinical service and their clinical data from electronic NHS databases.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Dr Jemma Longley | Contact | 023 8120 5154 | violetstudy@uhs.nhs.uk |
| Name | Affiliation | Role |
|---|---|---|
| Dr Jemma Longley | University Hospital Southampton NHS Foundation Trust | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospital Southampton NHS Foundation Trust | Recruiting | Southampton | SO16 6YD | United Kingdom |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| UNKNOWN |
| University of Oxford | OTHER |
Not provided
Not provided
Not provided
Blood, urine, vaginal fluid, primary tissue and ascitic fluid